Table 1.
Clinical and Demographic Data for the Derivation, Test, and Validation Cohorts
| Derivation Cohort | |||
|---|---|---|---|
| Variable | All | Survivors | Nonsurvivors |
| n | 341 | 232 | 109 |
| Median age (IQR) | 63 (51–73) | 61 (48–72) | 64 (54–76)a |
| Males, n (%) | 201 (58.9) | 142 (61.2) | 59 (54.1) |
| Median APACHE II (IQR)d | 27 (22–32) | 25 (20–30) | 31 (24–35)a |
| Median APACHE III (IQR)d | NA | NA | NA |
| Number of people with chronic disease (%)f | 165 (48.4) | 96 (41.4) | 69 (63.3)c |
| Mean days to death ± sd | NA | NA | 8.7 ± 7.9 |
| Median days to death (IQR) | NA | NA | 6 (2–13) |
| Number of people with septic shock (%) | 341 (100) | 232 (100) | 109 (100) |
| Number of people with a surgical diagnosis (%) | 78 (23) | 56 (24) | 22 (20) |
| Test Cohort | Validation Cohort | ||||
|---|---|---|---|---|---|
| All | Survivors | Nonsurvivors | All | Survivors | Nonsurvivors |
| 331 | 232 | 99 | 209 | 121 | 88 |
| 61 (50–72) | 58 (47–69) | 69 (56–76)a | 62 (51–71) | 63 (50–72) | 62 (53–71) |
| 229 (69.2)b | 164 (70.7) | 65 (59.6)c | 116 (55.5) | 67 (55.3) | 49 (55.7) |
| 23 (18–29)e | 22 (17–27) | 27 (20–32)a | NA | NA | NA |
| NA | NA | NA | 50 (37–79) | 51 (37–76) | 50 (38–82) |
| 95 (28.7)b | 56 (24.1) | 39 (35.8)c | 132 (63.2)b | 68 (56.2) | 64 (74.4)c |
| NA | NA | 11.1 ± 8.0e | NA | NA | 7.5 ± 6.9 |
| NA | NA | 10 (4–17)e | NA | NA | 5 (2–11) |
| 271 (81.9)b | 182 (78.4) | 89 (89.9)c | 209 (100) | 121 (100) | 88 (100) |
| 90 (27) | 68 (29) | 22 (22) | 8 (4)b | 8 (7) | 0 (0)c |
IQR = interquartile range, APACHE = Acute Physiology and Chronic Health Evaluation, NA = not applicable.
p < 0.05 versus respective survivors; Mann-Whitney U test.
p < 0.05 versus derivation cohort; chi-square test.
p < 0.05 versus respective survivors; chi-square test.
The derivation and test cohorts had APACHE II scores recorded, whereas the validation cohort had APACHE III scores recorded.
p < 0.05 versus derivation cohort; Mann-Whitney U test.
The presence of at least one of the following at study entry: New York Heart Association Class 4 congestive heart failure, chronic obstructive pulmonary disease, requirement for chronic dialysis, chronic hepatic failure, hematologic or metastatic solid organ malignancy, or requirement for chronic steroids.